GSK Completes $950 Million Acquisition of 35Pharma to Boost Pulmonary Hypertension Pipeline
MT Newswires Live
Apr 15
GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline.
The deal gives GSK full ownership of HS235, a clinical-stage, protein-based treatment targeting the activin receptor signalling pathway, a clinically validated target in pulmonary hypertension.
GSK said the candidate is designed with enhanced selectivity and could potentially reduce risks such as bleeding, pericardial effusion and dose-limiting increases in haemoglobin associated with current treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.